ライフサイエンスコーパス: acetylcholinesterase inhibitor

1 tor agonists) and organophosphate miticides (acetylcholinesterase inhibitors).

2 macological intervention using donepezil, an acetylcholinesterase inhibitor.

3 s examined in the presence of ambenonium, an acetylcholinesterase inhibitor.

4 g stable antiparkinsonian medications and no acetylcholinesterase inhibitors.

5 e, as four of the six approved therapies are acetylcholinesterase inhibitors.

6 of age, disease severity and baseline use of acetylcholinesterase inhibitors.

7 ves do not have the unwanted side effects of acetylcholinesterase inhibitors.

8 ntration in the neuromuscular junction using acetylcholinesterase inhibitors.

9 after acute and prolonged administration of acetylcholinesterase inhibitors.

10 variety of organophosphate insecticides and acetylcholinesterase inhibitors.

11 observed in 6 of 66 patients who received an acetylcholinesterase inhibitor, 65 of 69 patients who re

12 trast, nonselective ACh modulation using the acetylcholinesterase inhibitor (AChEI) donepezil improve

13 dynamics to determine ACh's effects, via the acetylcholinesterase inhibitor (AChEI) donepezil, on the

14 With the aim of reducing side effects of acetylcholinesterase inhibitors (AChEIs) during symptoma

15 Acetylcholinesterase inhibitors (AChEIs) have been propo

16 Notably, a concise synthesis of acetylcholinesterase inhibitors (AChEIs) scaffolds as po

17 meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutr

18 Alzheimer disease (AD) treatment, acetylcholinesterase inhibitors (AChEIs), have anti-infl

19 sure of GWV to organophosphate and carbamate acetylcholinesterase inhibitors (AChEis), including pyri

20 These drugs, known as acetylcholinesterase inhibitors (AChEIs), were first app

21 e unclear, but antidementia drugs (including acetylcholinesterase inhibitors [AChEIs] and memantine)

22 behavior; they are slightly resistant to the acetylcholinesterase inhibitor aldicarb, and they exhibi

23 The viable mutants are resistant to the acetylcholinesterase inhibitor aldicarb, indicating that

24 ced behavior and confirmed resistance to the acetylcholinesterase inhibitor aldicarb, suggesting a de

25 hermore, rab-3 animals were resistant to the acetylcholinesterase inhibitor aldicarb, suggesting that

26 naptic morphology and weak resistance to the acetylcholinesterase inhibitor aldicarb, they are signif

27 ctivity had delayed paralysis induced by the acetylcholinesterase inhibitor aldicarb, whereas mutants

28 muscular junction during lethargus using the acetylcholinesterase inhibitor aldicarb.

29 naling mutants and transgenic animals to the acetylcholinesterase inhibitor aldicarb.

30 ing the sensitivity of intact animals to the acetylcholinesterase inhibitor aldicarb.

31 al defects and show strong resistance to the acetylcholinesterase inhibitor aldicarb.

32 utants also exhibited hypersensitivity to an acetylcholinesterase inhibitor, aldicarb, uncovering def

33 f C. elegans to the paralyzing affects of an acetylcholinesterase inhibitor, aldicarb.

34 Of these, the acetylcholinesterase inhibitor and Alzheimer drug galant

35 with commonly available medications such as acetylcholinesterase inhibitors and beta2 adrenergic rec

36 nvolves local ACh release, is potentiated by acetylcholinesterase inhibitors and blocked by atropine

37 re also limited by common adverse effects of acetylcholinesterase inhibitors and limited availability

38 Acetylcholinesterase inhibitors and memantine hydrochlor

39 s to examine the safety of NMB reversal with acetylcholinesterase inhibitors and muscarinic anticholi

40 se Research Centre who subsequently received acetylcholinesterase inhibitors and underwent magnetic r

41 thout an aid, had no previous exposure to an acetylcholinesterase inhibitor, and did not have dementi

42 utica, Titusville, NJ) belongs to a class of acetylcholinesterase inhibitors approved for symptomatic

43 gging method, where unknown organophosphorus acetylcholinesterase inhibitors are "flagged" out of a c

44 Acetylcholinesterase inhibitors are commonly used to tre

45 +/- 6.7 years); 71% of the patients were on acetylcholinesterase inhibitors at baseline; mean Mini-M

46 Rivastigmine was equipotent to the specific acetylcholinesterase inhibitor BW284C51 and more potent

47 enhanced sIPSCs after pretreatment with the acetylcholinesterase inhibitor Bw284c51.

48 y of sacral VF neurons in the presence of an acetylcholinesterase inhibitor can be partially ascribed

49 administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce antinocicept

50 administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce effective pa

51 The favorable response to acetylcholinesterase inhibitors, despite a 15-year histo

52 ture was suggested by the fact that when the acetylcholinesterase inhibitor DFP was co-administered w

53 tors; however, in some cases the efficacy of acetylcholinesterase inhibitors diminishes over time.

54 nist carbachol and indirectly in vivo by the acetylcholinesterase inhibitor donepezil in rhesus monke

55 The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic res

56 ve M(1) PAM VU0453595 in comparison with the acetylcholinesterase inhibitor donepezil, M(1)/M(4) agon

57 y improved following a 24-week course of the acetylcholinesterase inhibitor donepezil.

58 milar in normal and lesioned animals and the acetylcholinesterase inhibitor, donepezil (1 mg/kg), pro

59 nspiring pharmacophoric features such as the acetylcholinesterase inhibitor donezepil and the tubulin

60 demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrabl

61 amates, estrogenic pesticides, and carbamate acetylcholinesterase inhibitors during the second trimes

62 ments of the neonatal rat spinal cord to the acetylcholinesterase inhibitor edrophonium (EDR).

63 The acetylcholinesterase inhibitor eserine reduced Off-EPSC1

64 y a continuous infusion of physostigmine, an acetylcholinesterase inhibitor, for the subsequent 8 sca

65 Galantamine, a centrally acting acetylcholinesterase inhibitor, has been shown to attenu

66 Acetylcholinesterase inhibitors have also been shown to

67 The beneficial effects of acetylcholinesterase inhibitors, however, are typically

68 lcholine receptor deficiency respond well to acetylcholinesterase inhibitors; however, in some cases

69 ke freely moving male rats, without using an acetylcholinesterase inhibitor in the perfusion medium.

70 ion tomography predict treatment response to acetylcholinesterase inhibitors in patients with dementi

71 ntinuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor

72 AD, and enhancing cholinergic signaling with acetylcholinesterase inhibitors is currently the primary

73 The response to acetylcholinesterase inhibitors is often disappointing.

74 Donepezil, an acetylcholinesterase inhibitor, is an approved drug for

75 oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).

76 medications include atypical antipsychotics, acetylcholinesterase inhibitors, memantine, antidepressa

77 carbachol (30-500 pmol per infusion) or the acetylcholinesterase inhibitor neostigmine (7.5-75 pmol

78 s, we microdialyzed a 0.1 mM solution of the acetylcholinesterase inhibitor neostigmine into the L7 l

79 One membrane was perfused with the acetylcholinesterase inhibitor neostigmine, while the ot

80 consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine.

81 dia, and levels of ACh were increased by the acetylcholinesterase inhibitor neostigmine.

82 d) mice by inhibiting ACh breakdown with the acetylcholinesterase inhibitor neostigmine.

83 p-like state caused by mPRF injection of the acetylcholinesterase inhibitor neostigmine.

84 racting the detrimental effects of long-term acetylcholinesterase inhibitors on the postsynaptic neur

85 1000 microM) but was greatly enhanced by the acetylcholinesterase inhibitor physostigmine (1-5 microM

86 The plant-derived acetylcholinesterase inhibitor physostigmine has previou

87 ist radioligand (-)-[(18)F]flubatine and the acetylcholinesterase inhibitor physostigmine to jointly

88 hippocampal (Experiment 2) injections of the acetylcholinesterase inhibitor physostigmine were admini

89 premise using systemic administration of the acetylcholinesterase inhibitor physostigmine, which has

90 intravenous cholinergic challenge using the acetylcholinesterase inhibitor, physostigmine (1 mg), or

91 ic activation by systemic application of the acetylcholinesterase inhibitor, physostigmine, resulted

92 treatment with donepezil, a centrally active acetylcholinesterase inhibitor, prevented and reversed o

93 plication of 10 microM neostigmine, a potent acetylcholinesterase inhibitor, prolonged the EPSC decay

94 sive, the prophylactic use of the reversible acetylcholinesterase inhibitor, pyridostigmine bromide (

95 e A, a sodium channel blocker and reversible acetylcholinesterase inhibitor, respectively, were capab

96 Treatment with acetylcholinesterase inhibitors resulted in worsened con

97 Acetylcholinesterase inhibitor reversal can cause respir

98 eliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce

99 Unlike galantamine, the acetylcholinesterase inhibitors rivastigmine and donepez

100 o acquired myasthenia gravis, treatment with acetylcholinesterase inhibitors should be avoided in DOK

101 gami chemiluminescent paper-based sensor for acetylcholinesterase inhibitors, showing high potential

102 For Alzheimer disease, this includes an acetylcholinesterase inhibitor such as donepezil for mil

103 vascular side effects usually attendant with acetylcholinesterase inhibitors such as neostigmine.

104 ribed treatments for Alzheimer's disease are acetylcholinesterase inhibitors, such as donepezil and g

105 nvestigating pharmacological therapies using acetylcholinesterase inhibitors, such as pyridostigmine

106 reviously been shown to confer resistance to acetylcholinesterase inhibitors, suggesting that they ma

107 allosteric muscarinic ligands, including the acetylcholinesterase inhibitor tacrine and the bis-pyrid

108 (arecoline, pilocarpine or oxotremorine), an acetylcholinesterase inhibitor (tacrine or E2020), or ni

109 Galantamine is an acetylcholinesterase inhibitor that also acts as a posit

110 e the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also acts as an allo

111 Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effe

112 oup and includes symptomatic treatment using acetylcholinesterase inhibitors, thymectomy and immunoth

113 e specific examples of the therapeutics from acetylcholinesterase inhibitors to recent anti-Abeta imm

114 and functional network enhancements with an acetylcholinesterase inhibitor treatment (donepezil) whe

115 are more likely to cognitively improve with acetylcholinesterase inhibitor treatment.

116 nd no evidence that age, disease severity or acetylcholinesterase inhibitor use influenced rate of de

117 (defined by hospital discharge diagnosis or acetylcholinesterase inhibitor use).

118 ce for influence by age, disease severity or acetylcholinesterase inhibitor use.

119 and Drug Administration-approved reversible acetylcholinesterase inhibitor used to treat mild to mod

120 Use of acetylcholinesterase inhibitors was prohibited.

121 xtended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 sub

122 f this study was to test the hypothesis that acetylcholinesterase inhibitors will attenuate the tachy

123 lyzes the hydrolysis of paraoxon and related acetylcholinesterase inhibitors with rate enhancements t